# Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion

> **NCT01377597** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 47 (actual)

## Conditions studied

- Retinal Vein Occlusion

## Interventions

- **DRUG:** ranibizumab

## Key facts

- **NCT ID:** NCT01377597
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2016-11-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01377597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01377597, "Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01377597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*